Drug Trial Radar · NCT00497146
The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4
Last checked: Nov 19, 2026Latest source record: Mar 12, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
227
Actual
Start
Feb 2008
Primary completion
Sep 2010
Study completion Mar 2012
Sponsor
- Lead sponsor
- AbbVie (prior sponsor, Abbott)AbbVie (ABBV)
- Sponsor type
- Industry
- Collaborators
- Massachusetts General Hospital
- First posted
- Jul 6, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the effects of paricalcitol capsules on cardiac structure and function over 48 weeks in patients with Stage 3/4 chronic kidney disease (CKD) who had left ventricular hypertrophy (LVH).
Conditions
- Chronic Kidney Disease
- Left Ventricular Hypertrophy
Interventions
paricalcitolDrug
2 µg capsule
placeboDrug
placebo capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Left Ventricular Mass Index (LVMI) Over 48 Weeks Measured by Cardiac Magnetic Resonance Imaging (MRI)Time frame: Baseline to 48 weeks
Locations
71 sites in 12 countries. Site status is shown where the registry gives one.
Site Reference ID/Investigator# 8062
Phoenix, Arizona
Site Reference ID/Investigator# 8867
Tempe, Arizona
Site Reference ID/Investigator# 8864
San Diego, California
Site Reference ID/Investigator# 7257
San Dimas, California
Site Reference ID/Investigator# 7727
Denver, Colorado
Site Reference ID/Investigator# 8861
Miami, Florida
Site Reference ID/Investigator# 7260
Orlando, Florida
Site Reference ID/Investigator# 7725
Tampa, Florida
Site Reference ID/Investigator# 7824
Tampa, Florida
Site Reference ID/Investigator# 18882
Meridian, Idaho
Site Reference ID/Investigator# 7823
Chicago, Illinois
Site Reference ID/Investigator# 7249
Evergreen Park, Illinois
Site Reference ID/Investigator# 7816
Bethesda, Maryland
Site Reference ID/Investigator# 18881
Rockville, Maryland
Site Reference ID/Investigator# 7817
Springfield, Massachusetts
Site Reference ID/Investigator# 7245
Detroit, Michigan
Site Reference ID/Investigator# 7248
Royal Oak, Michigan
Site Reference ID/Investigator# 8868
Kansas City, Missouri
Site Reference ID/Investigator# 7828
St Louis, Missouri
Site Reference ID/Investigator# 14442
Omaha, Nebraska
Site Reference ID/Investigator# 6567
Winston-Salem, North Carolina
Site Reference ID/Investigator# 7262
Winston-Salem, North Carolina
Site Reference ID/Investigator# 7826
Allentown, Pennsylvania
Site Reference ID/Investigator# 8865
Chattanooga, Tennessee
Site Reference ID/Investigator# 7261
Houston, Texas
Site Reference ID/Investigator# 8058
Houston, Texas
Site Reference ID/Investigator# 7830
San Antonio, Texas
Site Reference ID/Investigator# 7825
Murray, Utah
Site Reference ID/Investigator# 8866
Provo, Utah
Site Reference ID/Investigator# 7263
Fairfax, Virginia
Site Reference ID/Investigator# 8493
Adelaide, Australia
Site Reference ID/Investigator# 8506
Liverpool, Australia
Site Reference ID/Investigator# 8507
Parkville, Australia
Site Reference ID/Investigator# 9581
Reservoir, Australia
Site Reference ID/Investigator# 9582
Richmond, Australia
Site Reference ID/Investigator# 8500
Westmead, Australia
Site Reference ID/Investigator# 8245
Prague, Czechia
Site Reference ID/Investigator# 8246
Prague, Czechia
Site Reference ID/Investigator# 8499
Prague, Czechia
Site Reference ID/Investigator# 6692
Dortmund, Germany
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.